Th1/17 Hybrid CD4+ Cells Are Expanded in Bronchial Alveolar Lavage Fluid from Leukemia Patients with Checkpoint Inhibitor-Induced Pneumonitis

Leukemia, checkpoint inhibitors, pneumonitis, Th1/17 hybrid CD4+ cells, bronchial alveolar lavage
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Conclusion: Increased diffuse BM 18F-FDG uptake can be attributed to both bone marrow MI and benign etiologies. A decision tree based on C5.0 algorithm, combining PET/CT imaging and clinical features, is of potential use in discriminating BM malignant infiltration from patients with increased diffuse BM uptake.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Figures: 1
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research
Purpose: To investigate the significance of BCL-2 and BCL-6 expression in MYC positive-associate DLBCL lymphoma. Method: IHC was performed to evaluate the expression of BCL-2, BCL-6, MYC. Result: BCL-2 played a more import role compared to MYC in DEL patients, and BCL-6 negative expression might be a poor prognostic factor for DEL patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Abstract The chemokine receptor CXCR4 and its ligand stromal cell-derived factor-1 (SDF-1/CXCL12) are important players in the cross-talk among lymphoma, myeloma and leukemia cells and their microenvironments. In hematological malignancies and solid tumors, the overexpression of CXCR4 on the cell surface has been shown to be responsible for disease progression, increasing tumor cell survival and chemoresistance and metastasis to organs with high CXCL12 levels (e.g., lymph nodes and bone marrow (BM)). Furthermore, the overexpression of CXCR4 has been found to have prognostic significance for disease progression in ...
Source: Cytokine - Category: Molecular Biology Authors: Tags: Cytokine Source Type: research
Multiple myeloma (MM) is an incurable plasma cell dyscrasia with a five-year overall survival of 49.6% that is estimated to currently affect 118,539 people in the United States.1 Despite recent advances that have improved outcomes, MM patients inevitably become refractory to therapy; and, thus, must rely on a diversity of treatment options for long-term management of their disease.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Treatment of multiple myeloma (MM), a neoplasm of plasma cells, formerly dependent on alkylating drugs, corticosteroids, and autologous stem cell transplantation (ASCT), has changed dramatically in the past 20 years as three new classes of small molecule drugs (arbitrarily defined as having molecular weights of less than 900 kDa) - immunomodulators (IMiDs), proteasome inhibitors (PIs), and histone deacetylase (HDAC) blockers - have been introduced for the disease. Therapeutic options for MM expanded further in 2015 when two new monoclonal antibodies (daratumumab and elotuzumab) were approved by the FDA for MM.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Conditions:   Hematologic Diseases;   Cachexia; Cancer;   Leukemia;   Myeloma;   Lymphoma;   Cancer Intervention:   Other: whole-body electromyostimulation Sponsor:   University of Erlangen-Nürnberg Medical School Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We report the results of a prospective trial of lirilumab in patients with myelodysplastic syndrome(MDS). A total of 10 patients included. Higher-risk patients received lirilumab plus azacitidine, lower-risk received single agent lirilumab. Two patients achieved CR and 5 achieved marrow CR. Although the small sample size precludes definitive conclusions, the results of this study indicate the efficacy and safety of lirilumab in MDS.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Patients diagnosed with MYC-rearranged non-Burkitt aggressive B cell lymphoma (MYC-R), including those with double hit lymphoma, are at high risk for developing relapsed/refractory disease, even if treated with intensive front-line immunochemotherapy. It is common in clinical practice as well as clinical trials to perform an interim PET-CT scan (iPET) during front-line therapy for diffuse large B cell lymphoma, however the utility of iPET result in MYC-R patients with regards to predicting outcomes is unclear.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Treatment outcomes have improved in lymphoid malignancies but relapse remains inevitable in most patients. Everolimus (RAD) and lenalidomide (LEN) have shown clinical activity as single agents in patients with relapsed and refractory (R/R) Hodgkin and non-Hodgkin lymphomas. This Phase I/II trial for patients with R/R lymphoid malignancy opened at Mayo Clinic between January 2011 and May 2013 utilized a standard cohort of 3+3 design to determine the Maximum Tolerated Dose(MTD) of the combination.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: Leukemia | Lymphoma | Myeloma